Pacific Biosciences Of California (PACB) Total Debt (2010 - 2023)

Pacific Biosciences Of California has reported Total Debt for 13 years, with the latest figure at $96.2 million in Q3 2023.

• For the quarter ending Q3 2023, Total Debt changed N/A year-over-year to $96.2 million; the trailing twelve-month figure through Sep 2023 stood at $96.2 million (changed N/A YoY), and the FY2022 full-year result was $172.6 million, up 4316.43% from the prior year.
• Total Debt for Q3 2023 stood at $96.2 million, down from $186.3 million in the prior quarter.
• The five-year high for Total Debt was $186.3 million in Q2 2023, with the low at $3.9 million in Q4 2021.
• Average Total Debt over 4 years is $109.9 million, with a median of $134.4 million recorded in 2022.
• Year-over-year, Total Debt grew 7.78% in 2019 and soared 4316.43% in 2022.
• Tracing PACB's Total Debt over 4 years: stood at $15.8 million in 2019, then sank by 75.27% to $3.9 million in 2021, then soared by 4316.43% to $172.6 million in 2022, then plunged by 44.27% to $96.2 million in 2023.
• The last three Total Debt figures came in at $96.2 million (Q3 2023), $186.3 million (Q2 2023), and $184.4 million (Q1 2023), per Business Quant data.

Peer Comparison